Janssen Extends its Research and Licensing Agreement with SVI to Develop Therapies for Alzheimer’s Disease

 Janssen Extends its Research and Licensing Agreement with SVI to Develop Therapies for Alzheimer’s Disease

Janssen’s Tremfya (guselkumab) Receives FDA’s Approval for Moderate-to-Severe Plaque Psoriasis in Adults

Shots:

  • SVI to receive development milestones, royalties and option exercise fee. Janssen to exercise its option and will be responsible for all development of small molecule modulators of microglial function and inflammation for Alzheimer’s disease
  • In Aug’2017, Janssen collaborated with SVI to develop & commercialize small molecule modulators of microglial function and inflammation focusing the reduction in amyloid plaque burden and Alzheimer’s disease severity
  • The collaboration was facilitated by Johnson & Johnson Innovation and applied smart approaches to drug design utilizing the information about proteins structure as protein are considered as the building blocks and controls all function of the body

Click here to­ read full press release/ article | Ref: SVI | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post